Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Fuji
QuintilesIMS
Boehringer Ingelheim
US Department of Justice
Fish and Richardson
Queensland Health
Medtronic
Cantor Fitzgerald

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

« Back to Dashboard

Clinical Trials for Doxorubicin Hydrochloride (liposomal)

Trial ID Title Status Sponsor Phase Summary
NCT00001059 Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS Completed Amgen Phase 2 To evaluate the safety and efficacy of liposomal doxorubicin hydrochloride ( DOX-SL ) alone or in combination with bleomycin and vincristine in the long-term treatment of AIDS-related Kaposi's sarcoma. To determine whether the 3-drug combination enhances progression-free survival and quality of life. Liposomal formulations of chemotherapeutic agents increase drug accumulation in tumors, which permits disease palliation at relatively low doses and thus decreases some of the dose-limiting toxicity. Multi-agent therapy is considered to be more effective than single-agent therapy; therefore, DOX-SL will be combined with bleomycin and vincristine.
NCT00001059 Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS Completed Sequus Pharmaceuticals Phase 2 To evaluate the safety and efficacy of liposomal doxorubicin hydrochloride ( DOX-SL ) alone or in combination with bleomycin and vincristine in the long-term treatment of AIDS-related Kaposi's sarcoma. To determine whether the 3-drug combination enhances progression-free survival and quality of life. Liposomal formulations of chemotherapeutic agents increase drug accumulation in tumors, which permits disease palliation at relatively low doses and thus decreases some of the dose-limiting toxicity. Multi-agent therapy is considered to be more effective than single-agent therapy; therefore, DOX-SL will be combined with bleomycin and vincristine.
NCT00001059 Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 To evaluate the safety and efficacy of liposomal doxorubicin hydrochloride ( DOX-SL ) alone or in combination with bleomycin and vincristine in the long-term treatment of AIDS-related Kaposi's sarcoma. To determine whether the 3-drug combination enhances progression-free survival and quality of life. Liposomal formulations of chemotherapeutic agents increase drug accumulation in tumors, which permits disease palliation at relatively low doses and thus decreases some of the dose-limiting toxicity. Multi-agent therapy is considered to be more effective than single-agent therapy; therefore, DOX-SL will be combined with bleomycin and vincristine.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Doxorubicin Hydrochloride (liposomal)

Condition Name

Condition Name for Doxorubicin Hydrochloride (liposomal)
Intervention Trials
Ovarian Cancer 58
Breast Cancer 46
Multiple Myeloma 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Doxorubicin Hydrochloride (liposomal)
Intervention Trials
Ovarian Neoplasms 99
Breast Neoplasms 66
Fallopian Tube Neoplasms 42
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Doxorubicin Hydrochloride (liposomal)

Trials by Country

Trials by Country for Doxorubicin Hydrochloride (liposomal)
Location Trials
Italy 118
Spain 47
Canada 44
Germany 40
China 39
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Doxorubicin Hydrochloride (liposomal)
Location Trials
California 68
New York 60
Texas 48
Ohio 44
Florida 43
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Doxorubicin Hydrochloride (liposomal)

Clinical Trial Phase

Clinical Trial Phase for Doxorubicin Hydrochloride (liposomal)
Clinical Trial Phase Trials
Phase 4 6
Phase 3 48
Phase 2/Phase 3 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Doxorubicin Hydrochloride (liposomal)
Clinical Trial Phase Trials
Completed 122
Recruiting 67
Terminated 37
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Doxorubicin Hydrochloride (liposomal)

Sponsor Name

Sponsor Name for Doxorubicin Hydrochloride (liposomal)
Sponsor Trials
National Cancer Institute (NCI) 57
M.D. Anderson Cancer Center 12
Ortho Biotech, Inc. 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Doxorubicin Hydrochloride (liposomal)
Sponsor Trials
Other 286
Industry 189
NIH 60
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Teva
Fish and Richardson
Merck
US Department of Justice
Deloitte
McKesson
Cerilliant
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.